Titan’s Probuphine featured in Fortune

Titan’s Probuphine featured in Fortune

The online version of Fortune magazine has produced an article about the digital health revolution that discusses the contribution of Titan Pharmaceuticals (NASDAQ:TTNP) and its Probuphine implant as a maintenance treatment for opioid addiction.

Read More

Roth ups Conatus price target to $12

Roth ups Conatus price target to $12

Roth Capital Partners raised its price target for Conatus Pharmaceuticals (NASDAQ:CNAT) to $12 from $4, reflecting a revised valuation. The stock closed at $7.58 on April 21.

Read More

Clearside completes enrollment in HULK trial for DME

Clearside completes enrollment in HULK trial for DME

Clearside Biomedical (NASDAQ:CLSD) has competed enrollment in a Phase 1/2 clinical trial of CLS-TA for suprachoroidal administration of its proprietary suspension formulation of the corticosteroid, triamcinolone acetonide, with or without intravitreal Eylea for the treatment of diabetic macular edema (DME).

Read More

Leerink ups Immunogen to OP from MP

Leerink ups Immunogen to OP from MP

Leerink upgraded Immunogen (NASDAQ:IMGN) to “outperform” from “market perform” and raised its price target to $8 from $2 based on a “higher level of conviction” on lead asset, mirvetuximab soravtansine, providing an attractive risk/reward in context of the stock's current valuation. The stock closed at $3.24 on April 18.

Read More

Roth starts Auris Medical at buy

Roth starts Auris Medical at buy

Roth Capital Partners initiated coverage of Auris Medical Holding (NASDAQ:EARS), a Swiss biopharmaceutical company developing therapeutics that address unmet medical needs in otology, with a “buy” rating and price target of $4.50. The stock closed at 72 cents on April 12.

Read More